Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations

Repligen (RGEN) reported Q3 2026 revenue of $209.3M, beating estimates by 1.1% and growing 10.9% YoY. Adjusted EPS of $0.53 beat estimates by 14.6%. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Operating margin decreased to -14.1% from 8.9% YoY, while free cash flow margin fell to 18.1% from 23%.

Original reporting
Published Oct 27, 2026, 11:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 12:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations — source image
Decision brief

The 30-second read

$RGENBullishMed
01

Why it matters

The earnings beat and guidance raise expectations for near‑term revenue growth, supporting a bullish stance.

02

Market read

Earnings beat and guidance raise make RGEN a short‑term buying candidate.

03

What to watch

Potential headwinds from slower macro demand for biotech consumables.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Repligen (NASDAQ:RGEN) is a biotech company providing protein‑A purification and chromatography products.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

Repligen reported Q3 2026 results beating revenue and EPS estimates and raised full-year revenue and EPS guidance.

Expected impact

likely upward pressure as investors price in the beat and raised outlook

Evidence & confidence

Both earnings beat and guidance lift are fresh primary disclosures, providing a clear catalyst for short-term buying.

Market effects

Biotech tools sector may see modest uplift from Repligen's performance.

U.S. biotech stocks could benefit in early trading.

Limited to investors tracking small‑cap biotech earnings.

Counterpoint

Some analysts may view the modest revenue lift as insufficient given valuation.

Key entities

  • Repligen

    Biotech tools provider reporting Q3 2026 results.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.